MX2011012122A - Thiophene derivatives. - Google Patents

Thiophene derivatives.

Info

Publication number
MX2011012122A
MX2011012122A MX2011012122A MX2011012122A MX2011012122A MX 2011012122 A MX2011012122 A MX 2011012122A MX 2011012122 A MX2011012122 A MX 2011012122A MX 2011012122 A MX2011012122 A MX 2011012122A MX 2011012122 A MX2011012122 A MX 2011012122A
Authority
MX
Mexico
Prior art keywords
sup
compounds
thiophene derivatives
disclosed
pde4
Prior art date
Application number
MX2011012122A
Other languages
Spanish (es)
Inventor
Hesheng Zhang
Guanghuai Zeng
Yifei Gao
Original Assignee
Tianjin Hemay Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Bio Tech Co Ltd filed Critical Tianjin Hemay Bio Tech Co Ltd
Publication of MX2011012122A publication Critical patent/MX2011012122A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compounds of formula (I), preparation method thereof and pharmaceutical compositions containing such compounds are disclosed, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are defined in the description. The uses of said compounds for manufacturing a medicament for the treatment of PDE4-mediated diseases or conditions are also disclosed.
MX2011012122A 2009-05-14 2010-05-14 Thiophene derivatives. MX2011012122A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910068831 2009-05-14
PCT/CN2010/072767 WO2010130224A1 (en) 2009-05-14 2010-05-14 Thiophene derivatives

Publications (1)

Publication Number Publication Date
MX2011012122A true MX2011012122A (en) 2012-02-28

Family

ID=43071846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012122A MX2011012122A (en) 2009-05-14 2010-05-14 Thiophene derivatives.

Country Status (13)

Country Link
US (4) US8952178B2 (en)
EP (1) EP2431371B1 (en)
JP (1) JP5752114B2 (en)
KR (1) KR101514866B1 (en)
CN (5) CN107722036B (en)
AU (1) AU2010246749B8 (en)
BR (1) BRPI1012770B8 (en)
CA (1) CA2761845C (en)
ES (1) ES2441740T3 (en)
MX (1) MX2011012122A (en)
RU (1) RU2536865C2 (en)
WO (1) WO2010130224A1 (en)
ZA (1) ZA201108349B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130224A1 (en) 2009-05-14 2010-11-18 天津和美生物技术有限公司 Thiophene derivatives
US9126906B2 (en) 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
CN104447443B (en) * 2014-12-05 2016-07-27 新发药业有限公司 A kind of Apremilast and the preparation method of intermediate thereof
EP3280701B1 (en) 2015-04-09 2019-10-16 Zentiva K.S. A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
CZ2015383A3 (en) 2015-06-05 2016-12-14 Zentiva, K.S. Process for preparing apremilast key intermediate employing enzymatic cleavage of racemic amines
US9765026B2 (en) 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
TWI623316B (en) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
CN106543050B (en) * 2016-09-28 2018-04-10 中南大学湘雅医院 A kind of synthesis technique of Apremilast intermediate
CN109700804B (en) * 2017-03-01 2021-06-25 浙江大学 Tetrahydrocarbazole structure type androgen receptor antagonist and application thereof
EP3606908B1 (en) 2017-04-04 2020-06-17 Quimica Sintetica, S.A. Resolution of racemic beta-aminosulfone compounds
CN107011209A (en) * 2017-05-11 2017-08-04 蚌埠中实化学技术有限公司 A kind of new technique for synthesizing of the ethyoxyl cyanophenyl of 3 methoxyl group 4
US10570147B2 (en) 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
CN107941945B (en) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 Detection method of 3-ethoxy-4-methoxybenzonitrile
CN107966509B (en) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 Detection method of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine
CN108008035B (en) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 Method for detecting purity of 3-ethoxy-4-methoxybenzaldehyde
CN107827722B (en) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 Synthetic method of 3-ethoxy-4-methoxybenzaldehyde
CN107976501B (en) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 Detection method of 1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine
US11767295B2 (en) 2018-04-17 2023-09-26 Tianjin Hemay Pharmaceutical Co., Ltd. Isoindole derivative
US20210139498A1 (en) * 2018-05-02 2021-05-13 Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd Crystal forms of thiophene derivatives
CN109776526A (en) * 2019-01-23 2019-05-21 西南医科大学 Condensed cyclic triazole-(sulfonyl) Triazenes derivative and its preparation method and use
CN111821299A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of thiophene derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
KR20220145853A (en) * 2020-02-24 2022-10-31 쑤저우 롱보타이 파마슈티컬 씨오., 엘티디. PDE4 inhibitor compounds and their medical uses
WO2023116707A1 (en) * 2021-12-21 2023-06-29 赣州和美药业有限公司 Preparation for thiophene derivative

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023048A1 (en) * 1990-07-20 1992-01-23 Basf Ag Dicarboxylic acid imides, process for their preparation and their use as herbicides
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2006200033B8 (en) 1998-10-30 2008-09-11 Celgene Corporation Substituted phenethylsulfones and methods of reducing TNF-alpha levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003222034A1 (en) 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1761279A1 (en) 2004-05-31 2007-03-14 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
JP2008523102A (en) 2004-12-13 2008-07-03 セルジーン・コーポレーション Compositions containing PDE4 modulators and their use for the treatment or prevention of airway inflammation
CN100383139C (en) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 Piperidine-2,6-dione derivatives capable of inhibiting cell from releasing tumor necrosis factor
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CN1939922B (en) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2007139150A1 (en) 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR
CN101186612B (en) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
WO2009002746A1 (en) 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
EP2178370A4 (en) 2007-07-17 2011-01-12 Zalicus Inc Combinations for the treatment of b-cell proliferative disorders
TW200920381A (en) 2007-07-17 2009-05-16 Combinatorx Inc Treatments of B-cell proliferative disorders
WO2009013286A1 (en) 2007-07-24 2009-01-29 Novartis Ag Organic compounds
CA2718601A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20100009934A1 (en) 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010130224A1 (en) * 2009-05-14 2010-11-18 天津和美生物技术有限公司 Thiophene derivatives

Also Published As

Publication number Publication date
CN107722036B (en) 2020-09-04
EP2431371A1 (en) 2012-03-21
US10611775B2 (en) 2020-04-07
CA2761845A1 (en) 2010-11-18
US20190322684A1 (en) 2019-10-24
AU2010246749B8 (en) 2014-03-20
AU2010246749A8 (en) 2014-03-20
US9630975B2 (en) 2017-04-25
BRPI1012770B8 (en) 2021-05-25
CN107964016B (en) 2021-10-01
US20170197982A1 (en) 2017-07-13
CN107722036A (en) 2018-02-23
CN108059635B (en) 2021-10-01
US20140255342A1 (en) 2014-09-11
RU2011150786A (en) 2013-06-20
AU2010246749A1 (en) 2011-12-15
EP2431371B1 (en) 2013-10-09
KR101514866B1 (en) 2015-04-24
CN101885731A (en) 2010-11-17
ZA201108349B (en) 2013-01-30
EP2431371A4 (en) 2012-09-26
CN107964016A (en) 2018-04-27
KR20120028893A (en) 2012-03-23
US20120107269A1 (en) 2012-05-03
BRPI1012770B1 (en) 2020-10-20
RU2536865C2 (en) 2014-12-27
WO2010130224A1 (en) 2010-11-18
CN107501290A (en) 2017-12-22
CN108059635A (en) 2018-05-22
CA2761845C (en) 2015-01-20
AU2010246749B2 (en) 2013-09-05
JP5752114B2 (en) 2015-07-22
US10385062B2 (en) 2019-08-20
JP2012526731A (en) 2012-11-01
ES2441740T3 (en) 2014-02-06
BRPI1012770A2 (en) 2016-11-08
US8952178B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
MX2011012122A (en) Thiophene derivatives.
TW200833663A (en) Therapeutic agents
IN2012DN01233A (en)
WO2009155121A3 (en) Inhibitors of pi3 kinase
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
MY158504A (en) Fatty acid niacin conjugates and their uses
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MX2008002061A (en) Thiazolyl piperidine derivatives.
MX2009013501A (en) Piperidine compounds and uses thereof.
IN2012DN02139A (en)
UA104988C2 (en) Novel pyrone-indole derivatives and process for their preparation
GEP20135806B (en) Lactams as beta secretase inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008006795A3 (en) Indole compounds
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
TW200738627A (en) Trialkylsilyl-indoles
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2009130422A3 (en) N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway

Legal Events

Date Code Title Description
FG Grant or registration